Herkese harika bir merhaba! Bugün cilt sağlığı dünyasında ses getiren ve milyonlarca vitiligo hastasına umut ışığı olan inanılmaz bir gelişmeyi sizinle paylaşmak istiyorum. Ciltte aniden beliren beyaz lekelerle yaşamanın hem fiziksel hem de psikolojik olarak ne kadar zorlayıcı olabileceğini hepimiz biliyoruz.
Yıllardır vitiligo tedavisinde hep kremler, merhemler veya ışık tedavileri konuşuldu. Ancak dürüst olmak gerekirse; vücudun geniş alanlarına her gün krem sürmek oldukça zahmetliydi ve hastalığın ilerlemesini hızla durduracak pratik bir hap seçeneğimiz maalesef yoktu.
Büyük Müjde: Son klinik sonuçlar, günde tek doz alınan Upadacitinib adlı ilacın cilt rengini geri kazandırmada harika sonuçlar verdiğini ortaya koydu!
Sonuçlarda Öne Çıkanlar Neler?
Dünya genelinde yüzlerce yetişkin ve genç üzerinde denenen bu tedavi, kelimenin tam anlamıyla ezber bozuyor:
🎯 Yüz Bölgesinde Değişim: Tedaviyi alan her 4 kişiden biri, 48 haftanın sonunda yüzündeki renk kaybının %75'ten fazlasını geri kazandı!
🌟 Vücut Genelinde İyileşme: Hastaların %20'si vücutlarındaki lekelerin en az yarısının kapandığını gördü.
🛡️ Lekelerin İlerlemesi Durdu: Aktif vitiligosu olan kişilerin %76'sında yeni leke oluşumu ve mevcut lekelerin büyümesi ilk 8-12 hafta içinde tamamen durdu.
İşin en güzel tarafı, renk kazanımının 8. haftadan itibaren başlaması ve zaman geçtikçe etkisini artırarak devam etmesi. Hastalar da ciltlerindeki bu değişimden ve görünümün düzelmesinden son derece memnun kaldıklarını belirtiyor.
Yan etkiler konusunda ise süreç oldukça sakin geçti; hafif akne ve soğuk algınlığı dışında ciddi bir sorunla karşılaşılmadı. Cilt sağlığının geleceği için heyecan verici bir adım!
A Game-Changer in Dermatology: Is an Oral Pill Finally Here for Vitiligo?
Hey everyone! Today I want to share some incredibly exciting news that could completely transform the lives of millions living with vitiligo. If you or someone you love has been dealing with those unpredictable white patches on the skin, you know how challenging it can be — not just physically, but emotionally as well.
For years, the standard approach has been applying creams daily or undergoing lengthy light therapy sessions. But let’s be honest: covering extensive areas of the body with creams is tough, and option choices for stopping active progression have been very limited.
The Big News: Latest clinical studies show that an oral daily pill called Upadacitinib is delivering remarkable results in bringing skin color back!
What Did the Latest Results Reveal?
Researchers tested this oral treatment on hundreds of adults and teenagers across the globe, and the outcomes are truly inspiring:
🎯 Facial Repigmentation: Nearly 1 in 4 patients saw 75% or more of their facial skin color return after 48 weeks!
🌟 Total Body Impact: Around 20% of participants regained at least half of their overall body pigmentation.
🛡️ Stopping the Spread: For 76% of people with active vitiligo, the pill successfully stopped new patches from forming within the first 8 to 12 weeks.
What makes this even more encouraging is that skin repigmentation started appearing as early as week 8 and kept steadily improving over time without stalling. Patients also reported feeling much more confident and happy with how their skin looked!
As for side effects? The medication was generally well-tolerated, with mild acne and slight colds being the main mentions. Overall, it marks a huge step forward for dermatological health!
A Novel Immunomodulatory Strategy for Vitiligo and Celiac Disease
Abstract
Vitiligo and celiac disease are chronic autoimmune disorders affecting different organ systems yet sharing overlapping immunopathogenic mechanisms. Accumulating evidence identifies interleukin-15 (IL-15) as a central driver of pathogenic immune memory and tissue-specific inflammation in both conditions. TEV-408 is an investigational fully human monoclonal antibody designed to neutralize IL-15 signaling and thereby interrupt disease-sustaining immune circuits. This article provides an integrated overview of the biological rationale underlying IL-15 inhibition, the clinical development status of TEV-408, its differentiation from existing therapeutic approaches, and its emerging investment and market potential. Collectively, TEV-408 represents a potentially disease-modifying intervention with implications for multiple immune-mediated disorders.
Vitiligo and celiac disease are immune-mediated conditions characterized by chronic tissue damage driven by dysregulated adaptive immune responses. In vitiligo, melanocytes are selectively destroyed by autoreactive T cells, leading to progressive depigmentation of the skin. In celiac disease, gluten exposure triggers an inflammatory cascade that results in villous atrophy and impaired intestinal absorption. Despite advances in immunology, therapeutic options for both diseases remain limited, particularly with respect to systemic, disease-modifying interventions.
Recent immunological research has highlighted interleukin-15 (IL-15) as a pivotal cytokine sustaining pathogenic immune memory and cytotoxic effector responses in both disorders. Consequently, IL-15 blockade has emerged as a promising therapeutic strategy. TEV-408, a monoclonal antibody targeting IL-15, is currently under clinical investigation for both vitiligo and celiac disease, positioning it at the intersection of dermatology, gastroenterology, and translational immunology.
2. The Role of IL-15 in Autoimmune Pathogenesis
IL-15 is a pleiotropic cytokine essential for the survival, activation, and proliferation of natural killer (NK) cells and CD8⁺ memory T lymphocytes. Unlike many inflammatory cytokines, IL-15 is particularly important for maintaining tissue-resident immune memory, a feature increasingly recognized as a driver of chronic and relapsing autoimmune disease.
In vitiligo, IL-15 supports the persistence of resident memory T cells in the skin, which remain poised to re-initiate melanocyte destruction even after apparent clinical improvement. These cells are resistant to conventional immunosuppressive therapies, contributing to disease chronicity and relapse. Similarly, in celiac disease, IL-15 is upregulated in the intestinal epithelium in response to gluten exposure, where it promotes cytotoxic lymphocyte activation and epithelial cell death.
The convergence of IL-15–dependent immune mechanisms across these diseases provides a strong biological rationale for targeted IL-15 inhibition as a means of disrupting disease-sustaining immune circuits rather than merely suppressing downstream inflammation.
3. Mechanism of Action of TEV-408
TEV-408 is a fully human monoclonal antibody that binds IL-15 with high affinity, preventing its interaction with the IL-15 receptor complex and thereby inhibiting downstream signaling. Through selective IL-15 neutralization, TEV-408 aims to achieve targeted immunomodulation without inducing broad immunosuppression.
Preclinical studies have demonstrated that IL-15 blockade can eliminate pathogenic resident memory T cells and reverse depigmentation in vitiligo animal models. In early clinical studies involving healthy volunteers, TEV-408 showed evidence of on-target biological activity, including reductions in circulating IL-15 levels and IL-15–dependent immune cell populations, while preserving overall immune function.
In vitiligo, this mechanism may enable durable repigmentation by removing the immune memory responsible for melanocyte destruction. In celiac disease, IL-15 inhibition is expected to attenuate gluten-induced intestinal inflammation and epithelial damage, potentially offering protection against inadvertent gluten exposure.
4. Clinical Development Status
The clinical development of TEV-408 follows a multi-indication strategy:
Phase 1: Completed in healthy volunteers, demonstrating favorable safety, tolerability, and pharmacodynamic target engagement.
Vitiligo: Currently in Phase 1b clinical evaluation, focusing on safety and biological activity in affected patients.
Celiac Disease: Advanced to Phase 2a, assessing the ability of TEV-408 to reduce gluten-induced intestinal injury and clinical symptoms.
Importantly, the U.S. Food and Drug Administration (FDA) has granted TEV-408 Fast Track designation for celiac disease, reflecting the substantial unmet medical need and absence of approved pharmacological therapies. Initial patient-level data from ongoing trials are anticipated in 2026.
5. Differentiation from Existing Therapeutic Approaches
Current vitiligo treatments—such as topical corticosteroids, calcineurin inhibitors, phototherapy, and topical Janus kinase (JAK) inhibitors—primarily address local inflammation and are limited in scope, particularly for patients with extensive disease. No approved systemic therapy directly targets the immunological memory underlying vitiligo pathogenesis.
Similarly, celiac disease management relies almost exclusively on lifelong adherence to a strict gluten-free diet. While effective for many patients, dietary therapy does not address the underlying immune dysregulation and offers no pharmacological safeguard against accidental gluten exposure.
TEV-408 differentiates itself by targeting a core immunological driver shared across both diseases. By intervening upstream in the inflammatory cascade, IL-15 blockade holds the potential to modify disease course rather than simply controlling symptoms, positioning TEV-408 as a first-in-class therapeutic candidate.
6. Investment and Market Potential
The development of TEV-408 has attracted substantial financial backing, including a strategic investment agreement with Royalty Pharma valued at up to USD 500 million. Such high-value partnerships are typically reserved for assets with strong scientific rationale and blockbuster-level commercial potential.
From a market perspective, vitiligo affects approximately 0.5–2% of the global population, while celiac disease has a prevalence of roughly 1%, with many cases remaining undiagnosed. Market analyses suggest that each indication could independently support annual revenues exceeding USD 1 billion if an effective disease-modifying therapy becomes available.
Moreover, given IL-15’s involvement in additional autoimmune and inflammatory disorders, TEV-408 may offer future opportunities for indication expansion, further amplifying its long-term commercial value.
7. Conclusion
TEV-408 represents a novel immunotherapeutic approach that targets IL-15–mediated immune memory, a fundamental mechanism driving chronic autoimmunity in both vitiligo and celiac disease. Supported by a robust biological rationale, early clinical validation, regulatory momentum, and strong investor confidence, TEV-408 stands out as a promising disease-modifying candidate. Ongoing and future clinical trials will be critical in determining whether IL-15 inhibition can translate into durable clinical benefit and reshape treatment paradigms across multiple autoimmune diseases.
References (APA 7)
Calcalist. (2025). Royalty Pharma to invest up to $500 million in Teva’s TEV-408 program.
Vitiligo ve Çölyak Hastalığında Yenilikçi Bir İmmünomodülasyon Yaklaşımı
Özet
Vitiligo ve çölyak hastalığı, farklı organ sistemlerini etkileyen ancak ortak otoimmün mekanizmalar üzerinden gelişen kronik hastalıklardır. Son yıllarda interlökin-15 (IL-15) sitokininin bu hastalıkların patogenezinde merkezi bir rol oynadığı gösterilmiştir. TEV-408, IL-15’i nötralize etmeyi amaçlayan deneysel bir insan monoklonal antikorudur ve her iki hastalık için de potansiyel olarak hastalık-modifiye edici bir tedavi yaklaşımı sunmaktadır. Bu makale, TEV-408’in biyolojik mekanizmasını, klinik geliştirme sürecini, mevcut tedavilerden farklarını ve yatırım/pazar potansiyelini bütüncül bir çerçevede ele almaktadır.
Vitiligo ve çölyak hastalığı, bağışıklık sisteminin yanlış hedeflenmiş tepkileri sonucu gelişen otoimmün bozukluklardır. Vitiligo, melanositlerin bağışıklık aracılı yıkımı ile karakterize edilirken; çölyak hastalığı, gluten maruziyetine bağlı olarak ince bağırsak mukozasında gelişen inflamasyon ve villus atrofisi ile tanımlanır. Her iki hastalıkta da güncel tedaviler sınırlıdır ve hastalığın temel patofizyolojisini hedef alan onaylı sistemik biyolojik ajanlar bulunmamaktadır. Bu bağlamda IL-15 yolaklarının hedeflenmesi, otoimmün hastalık tedavisinde yeni bir paradigma olarak öne çıkmaktadır.
2. IL-15 ve Otoimmün Patogenez
IL-15, doğal öldürücü (NK) hücreler ve CD8⁺ bellek T hücrelerinin hayatta kalması ve proliferasyonu için kritik bir sitokindir. Otoimmün hastalıklarda IL-15’in aşırı ekspresyonu, patojenik bağışıklık hücrelerinin dokularda kalıcı hale gelmesine neden olmaktadır.
Vitiligoda IL-15, deride yerleşik bellek T hücrelerinin (resident memory T cells) devamlılığını destekleyerek melanositlere yönelik tekrar eden bağışıklık saldırılarını mümkün kılar. Çölyak hastalığında ise IL-15, gluten maruziyeti sonrası intraepitelyal lenfositlerin sitotoksik aktivitesini artırarak bağırsak epitelinde hasara yol açar. Bu ortak mekanizma, IL-15’i her iki hastalık için de cazip bir terapötik hedef haline getirmektedir.
3. TEV-408’in Etki Mekanizması
TEV-408, IL-15 sitokinine yüksek afiniteyle bağlanan ve onun biyolojik aktivitesini nötralize eden tam insan monoklonal antikorudur. IL-15 sinyalinin bloke edilmesiyle:
Vitiligoda melanosit yıkımından sorumlu bellek T hücrelerinin dokuda kalıcılığı azalır,
Bağışıklık sistemi genel olarak baskılanmadan, hedefe özgü bir immünomodülasyon sağlanır.
Hayvan modellerinde IL-15 blokajının vitiligoya bağlı depigmentasyonu tersine çevirebildiği gösterilmiştir. Sağlıklı gönüllülerde yapılan erken faz çalışmalarda ise TEV-408’in IL-15 seviyelerini düşürdüğü ve hedefe özgü biyolojik etki gösterdiği doğrulanmıştır.
4. Klinik Gelişim Süreci
TEV-408’in klinik geliştirme süreci çoklu endikasyon yaklaşımıyla ilerlemektedir:
Faz 1: Sağlıklı gönüllülerde güvenlilik, tolere edilebilirlik ve hedefe bağlanma doğrulanmıştır.
Vitiligo: Faz 1b aşamasında, hasta grubunda güvenlilik ve biyolojik etki değerlendirmesi sürmektedir.
Çölyak Hastalığı: Faz 2a aşamasına ulaşılmış olup, gluten maruziyeti sonrası bağırsak hasarının azaltılması temel sonlanım noktasıdır.
ABD Gıda ve İlaç Dairesi (FDA), çölyak hastalığındaki karşılanmamış klinik ihtiyaç nedeniyle TEV-408’e Fast Track statüsü tanımıştır. İlk hasta verilerinin 2026 yılında açıklanması beklenmektedir.
5. Mevcut Tedavilerden Farkı ve Klinik Avantajları
Vitiligoda mevcut tedaviler (topikal kortikosteroidler, fototerapi ve topikal JAK inhibitörleri) genellikle sınırlı etki alanına sahiptir ve hastalığın sistemik doğasını hedeflemez. TEV-408 ise potansiyel olarak ilk sistemik ve hastalık-modifiye edici tedavi olma özelliği taşımaktadır.
Çölyak hastalığında ise günümüzde tek kabul edilen tedavi ömür boyu glutensiz diyettir. TEV-408, diyet dışı ilk hedefe yönelik biyolojik tedavi olma potansiyeli ile bu alanda paradigmatik bir değişim yaratabilir.
6. Yatırım ve Pazar Potansiyeli
TEV-408’in geliştirilmesi, biyofarmasötik alanda ciddi bir finansal destekle sürdürülmektedir. Royalty Pharma tarafından sağlanan ve 500 milyon ABD dolarına kadar ulaşabilen yatırım, ilacın ticari ve klinik potansiyeline duyulan güveni yansıtmaktadır.
Pazar analizleri, vitiligo ve çölyak endikasyonlarının her biri için yıllık 1 milyar ABD dolarını aşan satış potansiyeline işaret etmektedir. Ayrıca IL-15’in diğer otoimmün hastalıklardaki rolü göz önüne alındığında, TEV-408’in endikasyon genişletme potansiyeli de bulunmaktadır.
7. Sonuç
TEV-408, IL-15 hedefli mekanizması sayesinde vitiligo ve çölyak hastalığında mevcut tedavilerin ötesine geçen, hastalık-modifiye edici bir yaklaşım sunmaktadır. Klinik geliştirme sürecinin erken aşamalarında olmasına rağmen, güçlü biyolojik rasyonel, düzenleyici destek ve yüksek yatırım ilgisi, bu ilacı otoimmün hastalıklar alanında dikkatle izlenmesi gereken bir aday haline getirmektedir.
Kaynakça (APA 7)
Calcalist. (2025). Royalty Pharma to invest up to $500M in Teva’s TEV-408 program.
Vitiligo is a chronic skin condition caused by an autoimmune response in which the body’s immune system attacks melanocytes—the pigment-producing cells in the skin. This leads to white patches, especially on visible areas such as the face, hands, and scalp. Affecting an estimated 0.5–2% of the global population, vitiligo often brings with it not only physical symptoms but also psychological and social challenges, particularly in individuals with darker skin tones where depigmentation is more pronounced.
A Sugar from Soil: The Promise of Microbial Therapy
Researchers at Northwestern University have made a major breakthrough by exploring a novel therapeutic approach derived from soil bacteria. They discovered that an exopolysaccharide (EPS)—a sugar-based compound secreted by the bacterium Bacillus subtilis—can reduce depigmentation in mice by up to 74%. Delivered through weekly injections, this compound effectively suppressed harmful “killer” T cells while boosting the number of protective “regulatory” T cells.
As lead researcher I. Caroline Le Poole noted, “It made a spectacular difference in our model, which is very aggressive. The results were quite surprising.”
Comparing to Existing Treatments
While treatments such as Opzelura (ruxolitinib cream), approved by the FDA in 2022, have shown promise—with roughly 30% of patients regaining at least 75% of their facial pigment—they are still far from a universal solution. The new microbial approach could potentially offer more sustainable and wide-ranging benefits, especially when used in conjunction with current therapies.
What’s Next: From Mice to Humans
This microbial therapy is still in the preclinical stage, tested only on mice so far. However, the researchers are actively working on developing human-compatible formulations, including injectables, dietary supplements, and topical creams. They also plan to examine how long the effects last, how frequently treatment would be required, and how well it might combine with existing options. Broader studies are also being considered to test this sugar compound in treating other autoimmune skin conditions.
Why This Matters
A New Therapeutic Paradigm: Using microbiome-derived compounds to regulate immune responses opens new avenues in the treatment of autoimmune disorders.
Psychosocial Impact: Even partial repigmentation or halting the progression of vitiligo could dramatically improve the quality of life and self-esteem of patients.
Broader Potential: If successful, this microbial approach may extend to other immune-related diseases, creating a powerful new treatment platform.
In conclusion, the Northwestern team’s findings represent a significant leap forward in the search for effective vitiligo treatments. By harnessing the healing potential of a natural compound produced by soil bacteria, researchers are paving the way for a future where microbial therapy may play a central role in reversing depigmentation and restoring both pigment and confidence in patients’ lives.
Vitiligo, melanositlerin (cilt pigment hücreleri) otoimmün saldırıya uğraması sonucu gelişen ve genellikle yüzde, ellerde, saçlı deride ve vücut açıklıklarında beyaz lekeler oluşturabilen kronik bir cilt hastalığıdır. Dünyada yaklaşık %0.5 ile 2 oranında görülür ve kalp hastalığı, hormonal bozukluklar, psikolojik stres gibi ek sağlık riskleriyle ilişkilendirilmiştirNews Center+3news.northwestern.edu+3LinkedIn+3. Koyu tenli bireylerde daha görünür olması, sosyal damgalanmayı ve özgüven kaybını tetikleyebilir .
Northwestern Üniversitesi araştırmacıları, Bacillus subtilis gibi toprak bakterilerinin salgıladığı bir eksopolisakkarit (EPS) bileşiğinin, vitiligo gelişen farelerde renksizleşmeyi %74 oranında azalttığını bulduThe Daily Northwestern+7Fierce Biotech+7LinkedIn+7. Haftalık enjeksiyonlarla uygulanan bileşik, pigmenti yok eden "killer T hücrelerinin" sayısını azaltırken, cildi koruyan "regülatör T hücreleri"ni artırdı .
2022 yılında FDA onayı alan Opzelura (ruxolitinib krem), yüz bölgesinde %75 pigment geri kazanımı sağlayabilen kullanıcıların oranını yaklaşık %30 olarak sınırlı tutuyorFierce Biotech+3news.northwestern.edu+3News Center+3. Bu durumu aşmayı hedefleyen mikrobiyal terapi, tek başına ya da mevcut tedavilerle birlikte hastalar için daha etkili bir seçenek sunabilir .
Gelecek Adımlar: Fareden İnsana
Araştırma şu an pre-klinik aşamada ve fare modelleriyle yürütüldü. Le Poole ekibi, bu bileşiği insan kullanımına uygun hale getirmek için farklı formlar (enjeksiyon, gıda takviyesi, topikal merhem) üzerinde çalışıyor. Ayrıca bu bileşiğin etkisinin süresi, kullanım sıklığı ve mevcut tedavilere olan uyumu da araştırmanın öncelikleri arasında . Laboratuvar şu anda diğer otoimmün cilt hastalıklarında da benzer sözdestekleyici etkileri keşfetmek üzere çok merkezli iş birlikleri yürütüyor .
Neden Bu Çalışma Önemli?
Yeni tedavi paradigması: Bağırsak ve mikroflora kaynaklı bileşiklerin otoimmün hastalıklarda tedavi amaçlı kullanılması, hastalığın temel mekanizmalarına doğrudan etki ederek yeni bir yaklaşım sunuyor.
Psikolojik etki: Vitiligo ile yaşayan bireyler için ilerleyişin durması ya da kısmen pigmentin geri kazanılması, yaşam kalitesini ve özgüveni dönüştürebilir.
Geniş potansiyel: Mikrobiyal bileşiklerin başka otoimmün rahatsızlıklarda da etkili olabileceği düşünülüyor—bu da sadık bir tedavi platformu oluşturabilir.
Sonuç olarak, Northwestern Üniversitesi’nin pre-klinik çalışması, toprak bakterilerinden gelen doğal bir bileşikin vitiligo fare modelinde hem hastalığı yavaşlattığını hem de pigmenti yeniden kazandırabildiğini gösteriyor. Etkinliğin insanlara taşınabilmesi için yeniden formülasyon, güvenlik ve klinik testler gibi adımlar atılmalı. Ancak bu çalışma, otoimmün hastalık tedavisinde mikrobiyal terapilerin potansiyelini en net şekilde ortaya koyuyor.
Vatandaşlar, sağlık profesyonelleri ve hasta toplulukları için bu gelişme sadece bireysel umut değil, aynı zamanda tıbbi araştırma ve tedavi paradigması açısından önemli bir adım olarak değerlendirilebilir.
Vitiligo causes smooth, milk‑white patches to appear on the skin when pigment‑producing cells (melanocytes) die off. Current treatments—creams, light therapy and newer JAK‑inhibitor creams—help some people, but relapses are common and no cure exists.
A fresh study used genetic sleuthing rather than clinical trials. By scanning DNA data from huge biobanks in the UK and Iceland, scientists asked: If someone is born with gene variants that naturally “turn down” different cholesterol‑related proteins, does their vitiligo risk change?
The Headline Finding
PCSK9 “turned down” → 20–30 % lower vitiligo risk.
People whose genes mimic the effect of PCSK9‑blocking injections (such as alirocumab or evolocumab) were significantly less likely to develop vitiligo.
Other cholesterol targets… no luck.
Variants that dampen HMGCR (the target of statins) or NPC1L1 (ezetimibe) offered no protection—one even showed a tiny risk increase.
It’s not about LDL cholesterol.
The protective effect remained even after accounting for traditional blood‑fat levels, pointing to a brand‑new immune pathway.
How Could a Cholesterol Drug Affect Skin Color?
PCSK9 isn’t just a “cholesterol switch.” It also nudges the immune system. The study identified several immune‑related proteins—CXCL12, CCN5, FCRL1, legumain—that rise when PCSK9 is active and track with higher vitiligo risk, while FGF‑2, a melanocyte‑friendly growth factor, falls. Blocking PCSK9 may rebalance these signals and spare pigment cells.
What Does This Mean for You?
Why It Matters
Existing drug, new use
PCSK9 inhibitors are already FDA‑approved for high cholesterol, so safety data are strong. Repurposing could be faster than inventing a brand‑new medicine.
Dual benefits possible
Imagine one injection that guards both your heart and your skin pigment.
Still early days
The evidence is genetic. Doctors must run clinical trials before prescribing these shots for vitiligo.
Should Patients Ask for PCSK9 Shots Now?
Not yet. These injections are expensive, require refrigeration, and are currently licensed only for people with stubbornly high LDL cholesterol. Until formal vitiligo trials confirm the benefit, dermatologists will stick with approved therapies.
But: if you already receive a PCSK9 inhibitor for heart reasons, this study offers an encouraging bonus.
Kolesterol ilacı, cilt hastalığına karşı koruma sağlayabilir mi?
PCSK9 adı verilen bir proteini baskılayan PCSK9 inhibitörleri kolesterol düşürücü enjeksiyonlar olarak biliniyor. Yeni bir genetik analiz, bu ilaçları “taklit eden” kalıtsal varyasyonlara sahip kişilerde vitiligo riskinin %20‑30 daha düşük olduğunu gösterdi. İlginç olan: Etki tamamen kolesterol düzeylerinden bağımsız görünüyor. Dermatology Times
Diğer kolesterol hedefleri aynı sonucu vermedi.
Statinlerin hedefi olan HMGCR ve ezetimibin hedefi NPC1L1 genleri incelendiğinde benzer bir koruma saptanmadı; hatta HMGCR’de risk hafifçe artabiliyor. Dermatology Times
Nasıl işe yarıyor?
Bilim insanları, PCSK9’un bağışıklık sistemi ile ilişkili yeni bir “immün‑metabolik yol” üzerinden etkili olabileceğini düşünüyor. Özellikle CXCL12, CCN5, FCRL1 ve legumain gibi bazı proteinlerin artışı vitiligo riskini yükseltirken, FGF2 adlı koruyucu proteinin bastırılması da tabloya katkıda bulunuyor. Dermatology Times
Çalışma Nasıl Yapıldı?
Mendelian Randomizasyon: Araştırmacılar, ilaç kullanımı yerine yüz binlerce kişinin genetik verilerini analiz ederek “ömrü boyunca ilaca maruz kalma” etkisini simüle ettiler.
Veri Tabanları: İngiltere UK Biobank ve İzlanda deCODE biyobankalarından gelen veriler birleştirildi.
Karşılaştırma: Üç farklı kolesterol hedefi (PCSK9, HMGCR, NPC1L1) riskle karşılaştırıldı. Yalnızca PCSK9 baskılanması anlamlı koruma sağladı. Dermatology Times
Neden Önemli?
Çifte Fayda Potansiyeli: Halihazırda kardiyoloji hastalarında kullanılan PCSK9 inhibitörleri, ileride vitiligo riskini de azaltmak veya hastalığı yavaşlatmak için değerlendirilebilir.
Yeni Tedavi Hedefleri: Çalışma, vitiligoda lipid dışı bağışıklık mekanizmalarının da rol oynadığını vurgulayarak araştırmacılara yeni moleküler hedefler sunuyor.
Klinik Deneme Kapısı: Genetik veriler umut verici olsa da, ilacın vitiligo hastalarında gerçekten işe yarayıp yaramadığını görmek için kontrollü klinik çalışmalar yapılması gerekiyor.
Hastalar ve Aileler İçin Ne Anlama Geliyor?
Mevcut Tedavinizi Değiştirmeyin: PCSK9 inhibitörleri henüz vitiligo tedavisi için onaylı değil. Bu bulgular geleceğe yönelik araştırma ipuçlarıdır.
Sağlıklı Yaşam ve Takip: Güneş koruması, stres yönetimi ve dermatoloğunuzun önerdiği tedaviler hâlâ en etkili yaklaşımlardır.
Umut Verici Bir Gelişme: Genetik çalışmalar vitiligo biyolojisini daha iyi anlamamıza yardımcı oluyor; her yeni keşif daha hedefli, yan etkisi düşük tedavilere bir adım daha yaklaştırıyor.
Öne Çıkan 3 Nokta
Detay
%20‑30 Risk Azalması
PCSK9 baskılanmasını “taklit eden” genler vitiligo riskini belirgin biçimde düşürüyor.
Kolesterolden Bağımsız
Koruyucu etki, LDL veya trigliserit düzeyleriyle açıklanamıyor; bağışıklık sistemi devrede.
Yeni Klinik Hedef
PCSK9 yolu, gelecekte hem kalp‑damar hem vitiligo tedavisinde “çifte görev” üstlenebilir.
Son Söz: Bilim, bazen beklenmedik bağlantılar kurar. Kalp ilacının vitiligo gibi cilt hastalığına umut olması da bunun güzel bir örneği. Şimdilik takipte kalın; klinik çalışma sonuçları geldikçe umutların gerçeğe dönüşme ihtimali artacak!
Vitiligo isn’t just a skin condition—it’s a deeply emotional and personal experience. It often begins quietly, with a pale spot that seems harmless, but for many, it grows into something that affects self-image, confidence, and social life. Here’s how one woman’s story reveals the everyday reality of living with vitiligo.
It Started with a Spot
Emily, a 26-year-old professional, noticed a faint patch on her face one day. At first, she brushed it off. But within weeks, more patches appeared—on her neck, arms, and legs. In less than a year, over 15% of her body was covered in depigmented spots.
Like many others, she hesitated to see a doctor. When she finally did, she was told it was “nothing to worry about.” That phrase would echo in her mind for months as her condition worsened.
The Long Road to a Diagnosis
Emily’s story is familiar to many with vitiligo. It took over 18 months and three different doctors before she received a proper diagnosis—and more importantly, someone who truly listened.
During that time, Emily tried everything: researching online, experimenting with creams, changing her diet, and trying supplements. She was searching not just for a cure, but for control over something she didn’t understand.
Finding the Right Support
Eventually, Emily found a dermatologist who offered both medical guidance and empathy. Together, they developed a treatment plan that included UV light therapy, topical medications, and support for her emotional well-being.
For the first time in two years, Emily felt hopeful—not because her skin was suddenly different, but because she was no longer fighting alone.
Beyond Skin: The Emotional Impact
Vitiligo isn’t just about appearance. The psychological impact can be overwhelming. Emily describes moments of avoiding mirrors, skipping social events, and fearing judgment in the workplace.
Many people underestimate how skin conditions like vitiligo can affect mental health. Anxiety, social withdrawal, and loss of self-esteem are part of the invisible struggle.
Looking Ahead: Healing in More Ways Than One
Emily’s journey with vitiligo is ongoing. Her goal isn’t perfection—it’s peace. She's learning to embrace her skin while pursuing treatments that work for her.
Stories like hers remind us that what vitiligo patients need most isn’t just a prescription—it’s compassion, early intervention, and a healthcare system that doesn’t dismiss their concerns.
Final Thoughts
Vitiligo may change how someone looks, but it doesn’t change who they are. With better awareness and understanding, we can create a more supportive world—one that recognizes the strength behind every patch of skin.
Vitiligo, a skin condition marked by the loss of pigment cells called melanocytes, affects millions of people around the world. Although not physically painful, its visible impact on the skin can deeply affect self-esteem and emotional well-being. In recent years, researchers have been exploring innovative treatment options—and one of the most promising developments is the use of JAK inhibitors.
How Do JAK Inhibitors Work?
JAK inhibitors target a specific signaling pathway in the immune system known as the JAK-STAT pathway. In people with vitiligo, the immune system mistakenly attacks melanocytes, leading to the white patches on the skin. By blocking this pathway, JAK inhibitors may help reduce the immune attack and allow melanocytes to survive and function.
What Does the Research Say?
Recent clinical studies suggest that both topical and oral JAK inhibitors can support the repigmentation process in vitiligo patients. That means the skin may begin to regain its natural color over time. While results are encouraging, the degree of improvement can vary from person to person, and not all patients respond equally.
The Road Ahead
Though JAK inhibitors show real promise, there’s still a long way to go before they become a routine treatment. Researchers are working to better understand the long-term safety and effectiveness of these drugs, especially when used over extended periods. There’s also growing interest in combining JAK inhibitors with other therapies, like light treatment, to enhance results.
In the future, personalized approaches—tailoring treatment to the individual patient’s biology and condition—may further improve outcomes.
In Summary
JAK inhibitors represent an exciting new chapter in vitiligo treatment. While more research is needed, the early signs are hopeful. For people living with vitiligo, this could be a step toward more effective and targeted care—and perhaps, a little more color returning to life.
Vitiligo is a condition that affects millions of people worldwide, causing patches of skin to lose their pigment. It’s more than just a cosmetic issue—vitiligo often brings emotional and psychological challenges as well. While the exact causes are still being explored, it’s widely understood that the immune system plays a major role in destroying pigment-producing cells known as melanocytes.
But what if nature already holds a key to slowing or even stopping this process?
A recent study has highlighted the potential of kaempferol, a natural compound found in many fruits and vegetables, and used in traditional Chinese medicine through the herb Tribulus terrestris. Researchers have found that kaempferol might protect melanocytes from a specific form of cell death called ferroptosis—a type of cell death triggered by iron buildup and oxidative stress.
In lab experiments, scientists used human melanocytes and exposed them to stress that would typically lead to cell death. When treated with kaempferol, these cells showed significant resistance. Their mitochondria—often referred to as the powerhouses of the cell—remained healthier, and levels of damaging molecules like reactive oxygen species (ROS) and iron were reduced.
The secret behind this protective effect appears to be kaempferol’s influence on GPX4, a protein that plays a vital role in preventing ferroptosis. When GPX4 was suppressed, kaempferol’s protective power was significantly weakened, suggesting a strong link between this protein and the compound’s effects.
While this doesn’t mean kaempferol is a cure for vitiligo, it opens exciting doors. By targeting ferroptosis and supporting melanocyte survival, natural compounds like kaempferol could one day be part of an effective treatment strategy—especially for a condition that currently has limited options.
As always, further research, especially in real-life clinical settings, is needed. But this study offers hope—and a reminder that sometimes, nature may already be ahead of us in finding solutions.
Vitiligo is the most common cause of depigmentation worldwide, with immunosuppressive treatments often being inefficient and prone to recurrence, making it essential to identify new therapeutic targets. Periplakin (PPL) has been identified and confirmed as a key factor in vitiligo-related depigmentation. Based on this, a series of selective PPL agonists, specifically benzenesulfonamides, have been developed. Among these, compound I-3 exhibits superior efficacy compared to ruxolitinib, the only FDA-approved treatment for vitiligo. I-3 has been shown to increase cAMP levels by regulating PPL, which enhances MITF expression, a key transcription factor in melanin biosynthesis. Additionally, I-3 promotes melanin production by regulating tryptophan metabolism. In summary, PPL is a promising drug target, and I-3 has strong potential for future treatment of vitiligo due to its high selectivity and favorable druggability.
The article on WATTPoultry.com highlights the use of Smyth line chickens, a breed prone to autoimmune diseases like vitiligo, as an important model for understanding human immune diseases. The research led by Professor Gisela Erf at the University of Arkansas explores immune responses by using a non-invasive feather sampling technique. This allows for a detailed study of immune cells in action without harming the animal, making the Smyth line an ethically favorable choice over traditional genetically modified models.
The article delves into the spontaneous development of vitiligo in these chickens, a condition that parallels the human form of the disease. Unlike genetically modified organisms (GMOs), these chickens naturally develop vitiligo, providing a more accurate and ethical model for studying autoimmunity and pigmentation diseases in humans.
Professor Erf's innovative feather sampling method leverages the chicken's feathers as a minimally invasive way to collect skin samples, which are then used to study various immune responses. This approach offers new insights into how immune cells behave in the context of autoimmune diseases and can be crucial for developing therapeutic strategies.
Moreover, the research underscores the need for collaboration between academic research and the poultry industry. The findings have implications not just for understanding human diseases but also for improving poultry health management. The study represents a fusion of animal science and immunology that could benefit both human medical research and agricultural practices.
Disorganisation of Basement Membrane Zone Architecture Impairs Melanocyte Residence in Vitiligo
This study investigates the causes of depigmentation in vitiligo patients by examining how disorganisation in the basement membrane zone (BMZ) architecture affects the residency and survival of melanocytes. The BMZ serves as the interface between the epidermis and dermis, maintaining the structural integrity of the skin. Vitiligo is a pigmentation disorder characterized by white patches on the skin, associated with the loss of melanocytes.
Key Findings:
Structural Disruptions in the BMZ: Using electron microscopy and immunofluorescence staining, the study observed abnormal BMZ architecture in vitiligo-affected skin samples. In healthy skin, the BMZ has a thin, continuous structure, while vitiliginous skin shows thickened, fragmented, and disorganized BMZ.
Role of MMP2: The study identified elevated expression of matrix metalloproteinase 2 (MMP2) in dermal fibroblasts of vitiligo-affected skin. MMP2 degrades key BM components such as collagen IV and laminin, leading to BM disruption and subsequent melanocyte loss.
Impaired Melanocyte Adhesion: In vitiligo, melanocyte adhesion to the BM is weakened due to reduced interactions between integrin β1-laminin and discoidin domain receptor 1 (DDR1)-collagen IV. This impaired adhesion results in melanocytes detaching from the BM and migrating to the upper layers of the epidermis.
Therapeutic Potential: MMP2 inhibitors were shown to reverse depigmentation in mouse models, indicating that targeting MMP2 could be a potential therapeutic strategy for vitiligo.
Conclusion: The study concludes that melanocyte loss in vitiligo is primarily linked to the disruption of BMZ integrity, largely due to overexpression of MMP2 in dermal fibroblasts. These findings open new avenues for therapeutic interventions to treat this challenging skin condition.
Reference:
Yang, F., Yang, L., Kuroda, Y., Lai, S., Takahashi, Y., Sayo, T., Namiki, T., Nakajima, K., Sano, S., Inoue, S., Tsuruta, D., & Katayama, I. (2024). Disorganisation of basement membrane zone architecture impairs melanocyte residence in vitiligo. The Journal of Pathology, 264(1), 30-41. DOI: 10.1002/path.6321.
This review article discusses the therapeutic potential of mesenchymal stem cells (MSCs) in treating vitiligo, a skin disorder characterized by the loss of pigmentation due to melanocyte dysfunction. The authors explore the role of oxidative stress and reactive oxygen species (ROS) in the pathogenesis of vitiligo, highlighting how ROS can damage melanocytes and contribute to disease progression.
Traditional treatments for vitiligo, such as glucocorticoid therapy, UV light therapy, and topical calcium-modulated phosphatase inhibitors, have limitations like long treatment durations, side effects, and frequent relapses. In contrast, MSCs offer a promising alternative due to their paracrine effects, which can reduce oxidative stress, promote tissue repair, and suppress autoimmune responses.
The article reviews the mechanisms by which MSCs exert antioxidant effects, focusing on several signaling pathways, including the Nrf2/ARE and PI3K/AKT pathways. These pathways help regulate oxidative stress and support melanocyte survival. MSCs can also transfer healthy mitochondria to damaged cells, improving cellular function and reducing oxidative stress. While MSC-based therapies show potential, further research is needed to clarify their safety, effectiveness, and application in clinical settings.
This overview suggests that MSCs could provide a novel, effective treatment approach for vitiligo by addressing its underlying oxidative stress and immune dysfunction.
*Reference: Yang, R.-l., Chen, S.-y., Fu, S.-p., Zhao, D.-z., Wan, W.-h., Yang, K., Lei, W., Yang, Y., Zhang, Q., & Zhang, T. (2023). Antioxidant mechanisms of mesenchymal stem cells and their therapeutic potential in vitiligo. Frontiers in Cell and Developmental Biology, 11, 1293101. doi: 10.3389/fcell.2023.1293101.
Ritlecitinib (under the commercial name LITFULO by Pfizer) is an anti-inflammatory and immunosuppressive drug that was recently approved for treatment of severe alopecia areata in the USA and Japan. The drug is being tested for treatment of vitiligo, ulcerative colitis, and Crohn’s disease, all of which are considered auto-immune disorders (Blair, 2023).
HOW DOES RITLECITINIB WORK?
Vitiligo is an auto-immune disorder, meaning that the body’s immune system mistakenly attacks and destroys its own cells – melanocytes (pigment cells), which results in formation of white patches. The immune system is incredibly complex and consists of various pathways and signalling molecules. Ritlecitinib is considered a kinase inhibitor, meaning it prevents kinases, which are certain proteins in the immune system, from working properly. This in turn blocks the immune pathways that are thoughts to contribute to development of auto-immune diseases, resulting in symptom improvements, such as repigmentation or stopping of disease progression in vitiligo (Xu et al., 2019; Pfizer Inc., 2023).
RITLECITINIB AND VITILIGO – A RECENT STUDY
A 48-week long phase 2b clinical trial on the effectiveness of ritlecitinib in vitiligo treatment has been published in February 2023 (Ezzedine et al., 2023). The trial compared patient groups taking various doses of ritlecitinib with a placebo group. The study assessed the changes in the proportion of vitiligo lesions on the face (Facial-Vitiligo Area Scoring Index, F- VASI) and found that a 50 mg tablet taken once daily resulted in significant improvements (up to 75% reduction in F-VASI compared to placebo at 24 weeks). Repigmentation began as early as 8 weeks after the start date, accelerated after 28 weeks, and was observed until 48 weeks when the trial ended. There was another important way to measure the effectiveness of ritlecitinib: the Patient Global Impression of Change-Vitiligo (PGIC-V) score, which is a 1-item questionnaire asking patients to report how much they feel their condition has changed. The responses range from ‘very much improved’ to ‘very much worse’. Patients across all treated groups reported meaningful changes, such as ‘much improved’ or ‘very much improved’ with the greatest proportion of patients reporting such changes at week 48 of the trial. The study also measured the safety of ritlecitinib and found it to be a safe drug with mild side effects, such as cough, sore throat, and headache. The side effects are likely because the drug lowers the immune defences of the body and makes it more prone to infections. Overall, the trial deemed ritlecitinib to be an effective and well-tolerated treatment for patients with active non-segmental vitiligo.
WHAT HAPPENS NOW?
The trial by Ezzedine et al. (2023) was a phase 2b trial, meaning that it tested the efficacy and safety of ritlecitinib in vitiligo in a relatively small patient group. Currently, there is a phase 3 trial underway (NCT05583526; Pfizer, 2023) with an estimated completion date in June 2025. Depending on the results of that trial, ritlecitinib may be approved for vitiligo treatment.
.png)
%20in%20treating%20oxidative%20stress%20in%20vitiligo.%20The%20diag.webp)
